Cargando…
Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome
Acquired von Willebrand syndrome (AVWS) in the setting of Waldenström macroglobulinemia (WM) is a challenging condition. No real standard of care is recommended for these patients, although the therapeutic strategy should include a rapid approach to the emergency bleeding events and to the underlyin...
Autores principales: | Ojeda-Uribe, Mario, Rimelen, Valérie, Marzullo, Cathérine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025649/ https://www.ncbi.nlm.nih.gov/pubmed/32104129 http://dx.doi.org/10.2147/JBM.S233059 |
Ejemplares similares
-
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021) -
Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
por: D’Aveni-Piney, M., et al.
Publicado: (2018) -
P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
por: Hueso, Thomas, et al.
Publicado: (2023) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013) -
Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)